FDA Approved: SUTENT — Supplemental Application (U.S. Pharmaceuticals)

View source ↗

Summary

The FDA approved a supplemental application for Sutent (sunitinib malate) submitted by U.S. Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor
• Pancreatic Neuroendocrine Tumor
• Renal Cell Carcinoma

Drugs mentioned

• Sutent (sunitinib)

Snippet

SUPPL AP for SUTENT (SUNITINIB MALATE)